P-A Barral1, M Saeed-Kilani2, F Tradi3, A Dabadie3, J Izaaryene3, J Soussan4, J-M Bartoli3, V Vidal3. 1. Department of radiology, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France. Electronic address: Pierre-Antoine.BARRAL@ap-hm.fr. 2. Department of radiology, centre hospitalier régional universitaire de Lille, 2, avenue Oscar-Lambret, 59000 Lille, France. 3. Department of radiology, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France. 4. Department of radiology, hôpital Nord, chemin des Bourelly, 13015 Marseille, France.
Abstract
PURPOSE: The purpose of this study was to evaluate the effectiveness of ethylene vinyl alcohol copolymer (Onyx) as a single embolic agent for percutaneous arterial treatment of hemorrhage due to uterine arteriovenous malformations (AVMs). MATERIALS AND METHODS: Twelve women (mean age, 33 years) with metrorrhagia due to uterine AVMs who were treated by percutaneous arterial embolization using Onyx as a single embolic agent were retrospectively included. The diagnosis of uterine AVM was suggested by pelvic ultrasound and/or magnetic resonance imaging findings and further confirmed by angiography. Clinical files and angiographic examinations were reviewed for angiographic findings, technical and clinical success, procedure complication and further pregnancies. Clinical success was defined by absence of metrorrhagia at 1 month following embolization. RESULTS: Sixteen arterial embolization procedures were performed. Angiographically, 6 women had high flow AVM and 6 had low flow AVM. The rate of technical and clinical success was 92% (11/12 patients). One woman with early repeat hemorrhage underwent two embolization procedures and further hysterectomy. No severe complications were observed after embolization. Three women (3/12; 25%) became pregnant following embolization including one full term pregnancy. CONCLUSION: In women with metrorrhagia due to AVM, arterial embolization with Onyx is effective and safe. Additional research is needed to confirm the possibility of future pregnancy after Onyx embolization.
PURPOSE: The purpose of this study was to evaluate the effectiveness of ethylene vinyl alcohol copolymer (Onyx) as a single embolic agent for percutaneous arterial treatment of hemorrhage due to uterine arteriovenous malformations (AVMs). MATERIALS AND METHODS: Twelve women (mean age, 33 years) with metrorrhagia due to uterine AVMs who were treated by percutaneous arterial embolization using Onyx as a single embolic agent were retrospectively included. The diagnosis of uterine AVM was suggested by pelvic ultrasound and/or magnetic resonance imaging findings and further confirmed by angiography. Clinical files and angiographic examinations were reviewed for angiographic findings, technical and clinical success, procedure complication and further pregnancies. Clinical success was defined by absence of metrorrhagia at 1 month following embolization. RESULTS: Sixteen arterial embolization procedures were performed. Angiographically, 6 women had high flow AVM and 6 had low flow AVM. The rate of technical and clinical success was 92% (11/12 patients). One woman with early repeat hemorrhage underwent two embolization procedures and further hysterectomy. No severe complications were observed after embolization. Three women (3/12; 25%) became pregnant following embolization including one full term pregnancy. CONCLUSION: In women with metrorrhagia due to AVM, arterial embolization with Onyx is effective and safe. Additional research is needed to confirm the possibility of future pregnancy after Onyx embolization.
Authors: Francesco Giurazza; Fabio Corvino; Andrea Paladini; Antonio Borzelli; Domenico Scognamiglio; Giulia Frauenfelder; Giuseppe Albano; Fabio Sirimarco; Raffaella Niola Journal: Case Rep Vasc Med Date: 2017-11-22
Authors: M Guida; D Maffucci; G Iannuzzi; M Giordano; G Luciano; L Di Benedetto; R Cantarella; A Rescigno; L Giugliano Journal: Int J Womens Health Date: 2018-11-21
Authors: Aditya Khurana; Patrick T Hangge; Hassan Albadawi; M-Grace Knuttinen; Sadeer J Alzubaidi; Sailendra G Naidu; J Scott Kriegshauser; Rahmi Oklu; Brian W Chong Journal: J Clin Med Date: 2018-05-09 Impact factor: 4.241